

SmartPA Criteria Proposal

Drug/Drug Class:	Antifungals, Topical PDL Edit
First Implementation Date:	July 10, 2014
Proposed Date:	March 17, 2022
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Many types of fungal germs (fungi) live harmlessly in the soil, on food, on our skin, and in other places in the environment. However, some types of fungi can thrive and multiply on the surface of the body causing infection of the skin, nails, mouth, or vagina. The most common fungi to cause skin infections are the tinea group of fungi. For example, tinea pedis (athlete's foot) is a common fungal infection of the toes and feet. Thrush is a common fungal infection of the mouth and vagina caused by an overgrowth of candida which is a yeast (a type of fungus). Small numbers of candida commonly live on the skin. However, certain conditions can cause candida to multiply and cause infection. Topical antifungals are used to treat these very common infections.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:

Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> • Alevazol[®] OTC • Butenafine Crm OTC • Ciclopirox 0.77% Crm/Susp • Clotrimazole Crm OTC • Clotrimazole Soln Rx • Clotrimazole/Betamethasone Crm • Ketoconazole Shampoo • Miconazole Crm/Pwd/Spray Pwd OTC • Nyamyc[®] Pwd • Nystatin Crm/Oint/Pwd • Nystop[®] Pwd • Terbinafine Crm OTC • Tolnaftate Crm/Pwd/Soln OTC • Zeasorb[®] AF 	<ul style="list-style-type: none"> • Azolen[™] Tinc OTC • CicloDan[®] • Ciclopirox 0.77% Gel • Ciclopirox 1% Shampoo • Ciclopirox 8% Kit/Soln • Clotrimazole Crm Rx • Clotrimazole Soln OTC • Clotrimazole/Betamethasone Lot • Econazole • Ertaczo[®] • Exelderm[®] • Extina[®] • Fungoid[®]-D • Jublia[®] • Kerydin[®] • Ketoconazole Crm/Foam • Ketodan[®] • Lamisil[®] Spray OTC • Loprox[®] • Lotrimin[®] • Luliconazole • Luzu[®] • Mentax[®] • Miconazole-Zinc-Petro 0.25-15% • Naftifine • Naftin[®] • Nizoral[®] A-D • Nystatin/Triamcinolone • Oxiconazole • Oxistat[®] • Sulconazole Crm/Soln • Tavaborole • Tinactin[®] • Tolnaftate Spray OTC • Vusion[®]

Type of Criteria: Increased risk of ADE
 Appropriate Indications

Preferred Drug List
 Clinical Edit

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Antifungal Agents, Topical
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 4 or more preferred agents
 - Documented trial period of preferred agents **OR**
 - Documented ADE/ADR to preferred agents

SmartPA PDL Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent[™] and Conduent Design[™] are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: "Topical Antifungals - Topical Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2022.
- Evidence-Based Medicine Analysis: "Topical Antifungal Agents", UMKC-DIC; January 2022.
- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.